TapImmune Inc. Stock Other OTC
Stocks
US8760333091
Biotechnology & Medical Research
|
End-of-day quote
Other OTC
|
||
| - USD | - |
|
| Market Cap | 20.01M 17.44M 16.43M 14.96M 28.05M 1.92B 28.09M 197M 75.84M 976M 75.16M 73.49M 3.15B | P/E 2026 * |
-2.02x | P/E 2027 * | -1.37x |
|---|---|---|---|---|---|
| Enterprise Value | 20.01M 17.44M 16.43M 14.96M 28.05M 1.92B 28.09M 197M 75.84M 976M 75.16M 73.49M 3.15B | EV / Sales 2026 * |
4.72x | EV / Sales 2027 * | 0.99x |
| Free-Float |
94.51% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: TapImmune Inc.
| 21/08/21 | Wall Street hoger gesloten | |
| 20/08/21 | Wall Street koerst af op hoger slot | |
| 20/08/21 | Wall Street richting lagere opening |
| Manager | Title | Age | Since |
|---|---|---|---|
Juan Vera
CEO | Chief Executive Officer | 46 | 01/05/2023 |
| Chief Operating Officer | 36 | 01/12/2023 | |
Patricia Allison
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Juan Vera
BRD | Director/Board Member | 46 | 17/10/2018 |
Norman Eansor
CHM | Chairman | 65 | 24/05/2022 |
Steven Elms
BRD | Director/Board Member | 62 | 06/08/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.91% | +4.13% | +3.44% | +31.22% | 46.68B | |
| +1.30% | +1.58% | +44.15% | +35.50% | 44.42B | |
| +0.95% | -6.02% | +342.72% | +532.41% | 41.32B | |
| +4.23% | +3.35% | +9.35% | +94.73% | 41.58B | |
| +1.11% | +1.45% | +11.52% | +45.96% | 30.14B | |
| +1.94% | +4.84% | +25.19% | +159.21% | 17.42B | |
| +0.37% | -10.32% | - | - | 15.6B | |
| +0.97% | +7.27% | +25.75% | +43.67% | 15.54B | |
| +0.24% | +25.43% | -11.57% | - | 14.08B | |
| Average | +1.46% | +3.55% | +56.32% | +134.67% | 29.64B | |
| Weighted average by Cap. | +1.72% | +2.11% | +70.44% | +142.59% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 4.24M 3.7M 3.48M 3.17M 5.95M 406M 5.96M 41.72M 16.08M 207M 15.93M 15.58M 668M | 20.19M 17.6M 16.58M 15.1M 28.3M 1.93B 28.34M 199M 76.51M 985M 75.82M 74.14M 3.18B |
| Net income | -11.84M -10.32M -9.72M -8.85M -16.6M -1.13B -16.62M -116M -44.87M -578M -44.46M -43.48M -1.86B | -18.09M -15.77M -14.86M -13.53M -25.37M -1.73B -25.4M -178M -68.58M -883M -67.96M -66.45M -2.85B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
